{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:01:00Z","timestamp":1790190060286,"version":"4.1.0"},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Guidelines recommend liposomal amphotericin B (L-AMB) at 5\u201310 mg\/kg\/day as first-line therapy for invasive mucormycosis, but whether doses exceeding 5\u20136 mg\/kg\/day improve outcomes enough to justify added nephrotoxicity and cost remains unclear. We critically appraised pharmacokinetic, preclinical, and clinical evidence from 58 publications, defining standard-dose L-AMB as 5\u20136 mg\/kg\/day and high-dose (HD) L-AMB as &amp;gt;6 mg\/kg\/day. Animal models show dose-dependent efficacy, but the only prospective trial (Ambizygo) examining HD-L-AMB was a single-arm pilot trial whose response rates were similar to historical 5 mg\/kg\/day cohorts. Retrospective studies have not found survival benefit favoring HD L-AMB, with consistently higher rates of nephrotoxicity. Saturable pharmacokinetics and altered liposome distribution at doses &amp;gt;10 mg\/kg\/day may explain this lack of benefit. Routine dose escalation beyond 5\u20136 mg\/kg\/day is not supported by current evidence; early diagnosis, surgical debridement, and reversal of immunosuppression appear more critical. However, selected cases may still warrant higher L-AMB doses based on individualized risk\u2013benefit assessment.<\/jats:p>","DOI":"10.1093\/infdis\/jiag336","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T11:41:58Z","timestamp":1784374918000},"page":"331-341","source":"Crossref","is-referenced-by-count":0,"title":["Does the Evidence Support High-Dose Liposomal Amphotericin B in the Treatment of Mucormycosis?"],"prefix":"10.1093","volume":"234","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2002-4339","authenticated-orcid":false,"given":"Russell E","family":"Lewis","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine, University of Padua , Padua ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8051-2940","authenticated-orcid":false,"given":"Dimitrios P","family":"Kontoyiannis","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"2026092314180881400_jiag336-B1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11046-025-00954-6","article-title":"A global analysis of cases of mucormycosis recorded in the European Confederation of Medical Mycology\/International Society for Human and Animal Mycology (ECMM\/ISHAM) Zygomyco.net registry from 2009 to 2022","volume":"190","author":"Skiada","year":"2025","journal-title":"Mycopathologia"},{"key":"2026092314180881400_jiag336-B2","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad704","article-title":"A systematic review of the therapeutic outcome of mucormycosis","volume":"11","author":"Sigera","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026092314180881400_jiag336-B3","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ijantimicag.2019.01.002","article-title":"Contemporary management and clinical outcomes of mucormycosis: a systematic review and meta-analysis of case reports","volume":"53","author":"Jeong","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2026092314180881400_jiag336-B4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3324\/haematol.2012.065110","article-title":"Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3)","volume":"98","author":"Skiada","year":"2013","journal-title":"Haematologica"},{"key":"2026092314180881400_jiag336-B5","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2026092314180881400_jiag336-B6","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1182\/blood-2011-03-316430","article-title":"How I treat mucormycosis","volume":"118","author":"Kontoyiannis","year":"2011","journal-title":"Blood"},{"key":"2026092314180881400_jiag336-B7","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/jac\/dkv236","article-title":"Prospective pilot study of high-dose (10 mg\/kg\/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis","volume":"70","author":"Lanternier","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2026092314180881400_jiag336-B8","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jac\/dkr375","article-title":"The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial","volume":"67","author":"Spellberg","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2026092314180881400_jiag336-B9","article-title":"Prognostic association of liposomal amphotericin B doses above 5 mg\/kg\/d in mucormycosis: a nationwide epidemiologic and treatment analysis in Japan","volume":"10","author":"Tashiro","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026092314180881400_jiag336-B10","first-page":"241","article-title":"Improving peer review of systematic reviews and related review types by involving librarians and information specialists as methodological peer reviewers: a randomised controlled trial","volume":"30","author":"Rethlefsen","year":"2025","journal-title":"BMJ Evid Based Med"},{"key":"2026092314180881400_jiag336-B11","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nchembio.1496","article-title":"Amphotericin forms an extramembranous and fungicidal sterol sponge","volume":"10","author":"Anderson","year":"2014","journal-title":"Nat Chem Biol"},{"key":"2026092314180881400_jiag336-B12","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s41594-021-00685-4","article-title":"Fungicidal amphotericin B sponges are assemblies of staggered asymmetric homodimers encasing large void volumes","volume":"28","author":"Lewandowska","year":"2021","journal-title":"Nat Struct Mol Biol"},{"key":"2026092314180881400_jiag336-B13","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02383-17","article-title":"The viscoelastic properties of the fungal cell wall allow traffic of AmBisome as intact liposome vesicles","volume":"9","author":"Walker","year":"2018","journal-title":"mBio"},{"key":"2026092314180881400_jiag336-B14","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.tox.2005.07.023","article-title":"Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity","volume":"216","author":"Szebeni","year":"2005","journal-title":"Toxicology"},{"key":"2026092314180881400_jiag336-B15","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1093\/cid\/ciz076","article-title":"Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal amphotericin B","volume":"68","author":"Groll","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026092314180881400_jiag336-B16","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1128\/AAC.50.2.674-684.2006","article-title":"Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models","volume":"50","author":"Andes","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314180881400_jiag336-B17","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1128\/AAC.45.3.922-926.2001","article-title":"Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model","volume":"45","author":"Andes","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314180881400_jiag336-B18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1128\/AAC.50.2.469-473.2006","article-title":"Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis","volume":"50","author":"Wiederhold","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314180881400_jiag336-B19","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1128\/AAC.04723-14","article-title":"Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus","volume":"59","author":"Al-Nakeeb","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314180881400_jiag336-B20","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1128\/AAC.47.10.3343-3344.2003","article-title":"Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae","volume":"47","author":"Ibrahim","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314180881400_jiag336-B21","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1128\/AAC.01222-09","article-title":"Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis","volume":"54","author":"Lewis","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314180881400_jiag336-B22","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/jac\/dks521","article-title":"High-dose induction liposomal amphotericin B followed by de-escalation is effective in experimental Aspergillus terreus pneumonia","volume":"68","author":"Lewis","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2026092314180881400_jiag336-B23","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01545-23","article-title":"Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B","volume":"68","author":"Gebremariam","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314180881400_jiag336-B24","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00380-22","article-title":"The combination treatment of fosmanogepix and liposomal amphotericin B is superior to monotherapy in treating experimental invasive mold infections","volume":"66","author":"Gebremariam","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314180881400_jiag336-B25","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1093\/jac\/dkab233","article-title":"Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis","volume":"76","author":"Gebremariam","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026092314180881400_jiag336-B26","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1128\/AAC.00313-13","article-title":"Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis","volume":"57","author":"Luo","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314180881400_jiag336-B27","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s10156-010-0071-7","article-title":"Comparative study of the efficacy of liposomal amphotericin B and amphotericin B deoxycholate against six species of Zygomycetes in a murine lethal infection model","volume":"16","author":"Takemoto","year":"2010","journal-title":"J Infect Chemother"},{"key":"2026092314180881400_jiag336-B28","first-page":"179","article-title":"Effect of tissue penetration on AmBisome efficacy","volume":"4","author":"Adler-Moore","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"2026092314180881400_jiag336-B29","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.1093\/cid\/ciz064","article-title":"Preclinical safety, tolerability, pharmacokinetics, pharmacodynamics, and antifungal activity of liposomal amphotericin B","volume":"68","author":"Adler-Moore","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026092314180881400_jiag336-B30","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1128\/AAC.46.3.834-840.2002","article-title":"Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314180881400_jiag336-B31","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1023\/A:1018997730462","article-title":"Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome\u00ae) in beagle dogs","volume":"16","author":"Bekersky","year":"1999","journal-title":"Pharm Res"},{"key":"2026092314180881400_jiag336-B32","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1023\/A:1007605024942","article-title":"Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (Ambisome\u00ae): a 91-day study in rats","volume":"17","author":"Bekersky","year":"2000","journal-title":"Pharm Res"},{"key":"2026092314180881400_jiag336-B33","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkaf473","article-title":"Liposomal amphotericin B and renal safety: review of the evidence and clinical considerations","volume":"81","author":"Maertens","year":"2026","journal-title":"J Antimicrob Chemother"},{"key":"2026092314180881400_jiag336-B34","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02673-18","article-title":"In vitro and in vivo exposure-effect relationship of liposomal amphotericin B against Aspergillus fumigatus","volume":"63","author":"Siopi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314180881400_jiag336-B35","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/infdis\/152.5.1037","article-title":"Distribution and activity of amphotericin B in humans","volume":"152","author":"Christiansen","year":"1985","journal-title":"J Infect Dis"},{"key":"2026092314180881400_jiag336-B36","article-title":"Experimental models to study the pathogenesis and treatment of mucormycosis","volume":"10","author":"Ben-Ami","year":"2024","journal-title":"J Fungi (Basel)"},{"key":"2026092314180881400_jiag336-B37","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1128\/JCM.00318-16","article-title":"Role of antifungal susceptibility testing in non-Aspergillus invasive mold infections","volume":"54","author":"Lamoth","year":"2016","journal-title":"J Clin Microbiol"},{"key":"2026092314180881400_jiag336-B38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179136","article-title":"Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: epidemiology and microbiological characterization of the isolates","volume":"12","author":"Guinea","year":"2017","journal-title":"PLoS One"},{"key":"2026092314180881400_jiag336-B39","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2026092314180881400_jiag336-B40","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00497-17","article-title":"Pharmacodynamics and biodistribution of single-dose liposomal amphotericin B at different stages of experimental visceral leishmaniasis","volume":"61","author":"Voak","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314180881400_jiag336-B41","doi-asserted-by":"crossref","first-page":"7340","DOI":"10.1128\/AAC.01427-16","article-title":"Population pharmacokinetics of liposomal amphotericin B in immunocompromised children","volume":"60","author":"Lestner","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314180881400_jiag336-B42","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1128\/AAC.00265-11","article-title":"Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients","volume":"56","author":"Wurthwein","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314180881400_jiag336-B43","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1128\/AAC.42.9.2391","article-title":"Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients","volume":"42","author":"Walsh","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314180881400_jiag336-B44","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/jac\/dkl141","article-title":"Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion","volume":"57","author":"Vogelsinger","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2026092314180881400_jiag336-B45","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/AAC.45.12.3487-3496.2001","article-title":"Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study","volume":"45","author":"Walsh","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314180881400_jiag336-B46","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/AAC.46.3.828-833.2002","article-title":"Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314180881400_jiag336-B47","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1099\/jmm.0.012401-0","article-title":"A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever","volume":"58","author":"Ellis","year":"2009","journal-title":"J Med Microbiol"},{"key":"2026092314180881400_jiag336-B48","doi-asserted-by":"crossref","first-page":"S464","DOI":"10.1093\/ofid\/ofad500.890","article-title":"Clinical outcomes in patients with high vs. standard dose liposomal amphotericin B for invasive mucormycosis","volume":"10","author":"Valiante","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026092314180881400_jiag336-B49","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2023-9-1","article-title":"High-dose amphotericin: yay or nay? A case series and literature review","volume":"13","author":"Stover","year":"2024","journal-title":"Drugs Context"},{"key":"2026092314180881400_jiag336-B50","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cmi.2018.07.011","article-title":"The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports","volume":"25","author":"Jeong","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2026092314180881400_jiag336-B51","article-title":"Disseminated mucormycosis in immunocompromised children: are new antifungal agents making a difference? A multicenter retrospective study","volume":"7","author":"Elitzur","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"2026092314180881400_jiag336-B52","article-title":"Introduction of a comprehensive diagnostic and interdisciplinary management approach in haematological patients with mucormycosis: a pre and post-intervention analysis","volume":"6","author":"Risum","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2026092314180881400_jiag336-B53","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2026092314180881400_jiag336-B54","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/bjh.16329","article-title":"Mucormycosis in children with haematological malignancies is a salvageable disease: a report from the Israeli Study Group of Childhood Leukemia","volume":"189","author":"Elitzur","year":"2020","journal-title":"Br J Haematol"},{"key":"2026092314180881400_jiag336-B55","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1439-0507.2008.01525.x","article-title":"Nephrotoxicity in the setting of invasive fungal diseases","volume":"51(Suppl 1)","author":"Ullmann","year":"2008","journal-title":"Mycoses"},{"key":"2026092314180881400_jiag336-B56","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa2111904","article-title":"Single-dose liposomal amphotericin B treatment for cryptococcal meningitis","volume":"386","author":"Jarvis","year":"2022","journal-title":"N Engl J Med"},{"key":"2026092314180881400_jiag336-B57","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa0903627","article-title":"Single-dose liposomal amphotericin B for visceral leishmaniasis in India","volume":"362","author":"Sundar","year":"2010","journal-title":"N Engl J Med"},{"key":"2026092314180881400_jiag336-B58","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-229612","article-title":"Treatment of pulmonary blastomycosis with high-dose liposomal amphotericin B in a patient receiving extracorporeal membrane oxygenation","volume":"12","author":"Servais","year":"2019","journal-title":"BMJ Case Rep"},{"key":"2026092314180881400_jiag336-B59","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejpb.2020.03.001","article-title":"In vitro - in vivo relations for the parenteral liposomal formulation of amphotericin B: a clinically relevant approach with PBPK modeling","volume":"159","author":"D\u00edaz de Le\u00f3n-Ortega","year":"2021","journal-title":"Eur J Pharm Biopharm"},{"key":"2026092314180881400_jiag336-B60","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejpb.2020.07.025","article-title":"In vitro in vivo relations for the parenteral liposomal formulation of amphotericin B: a biorelevant and clinically relevant approach","volume":"159","author":"Diaz de Leon-Ortega","year":"2021","journal-title":"Eur J Pharm Biopharm"},{"key":"2026092314180881400_jiag336-B61","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.3324\/haematol.2012.083063","article-title":"Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"key":"2026092314180881400_jiag336-B62","doi-asserted-by":"crossref","first-page":"811.e1","DOI":"10.1016\/j.cmi.2016.03.029","article-title":"Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis","volume":"22","author":"Kyvernitakis","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2026092314180881400_jiag336-B63","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab113","article-title":"When azoles cannot be used: the clinical effectiveness of intermittent liposomal amphotericin prophylaxis in hematology patients","volume":"8","author":"Batchelor","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026092314180881400_jiag336-B64","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ads7369","article-title":"A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response","volume":"17","author":"Gu","year":"2025","journal-title":"Sci Transl Med"},{"key":"2026092314180881400_jiag336-B65","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41564-020-00837-0","article-title":"Mucoricin is a ricin-like toxin that is critical for the pathogenesis of mucormycosis","volume":"6","author":"Soliman","year":"2021","journal-title":"Nat Microbiol"},{"key":"2026092314180881400_jiag336-B66","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2512042123","article-title":"Early adjunct anti-PD-L1 immunotherapy improves outcomes and restores infection-induced immune paralysis in mice with invasive pulmonary mucormycosis","volume":"123","author":"Wurster","year":"2026","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026092314180881400_jiag336-B67","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.838344","article-title":"Blockade of the PD-1\/PD-L1 immune checkpoint pathway improves infection outcomes and enhances fungicidal host defense in a murine model of invasive pulmonary mucormycosis","volume":"13","author":"Wurster","year":"2022","journal-title":"Front Immunol"},{"key":"2026092314180881400_jiag336-B68","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s41586-023-06710-4","article-title":"Tuning sterol extraction kinetics yields a renal-sparing polyene antifungal","volume":"623","author":"Maji","year":"2023","journal-title":"Nature"},{"key":"2026092314180881400_jiag336-B69","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/cid\/ciad440","article-title":"Oral lipid nanocrystal amphotericin B for cryptococcal meningitis: a randomized clinical trial","volume":"77","author":"Boulware","year":"2023","journal-title":"Clin Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag336\/69699349\/jiag336.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/3\/331\/69699349\/jiag336.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/3\/331\/69699349\/jiag336.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:18:21Z","timestamp":1790187501000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/234\/3\/331\/8739229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":69,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7,21]]},"published-print":{"date-parts":[[2026,9,23]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag336","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,15]]},"published":{"date-parts":[[2026,7,21]]}}}